AALL1732, A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy (CTMS# 19-0169)
Lay Description
Category
- Cancers and Other Neoplasms
- IRB Number
- 20190839HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- -
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Study Contact
Regulatory Point of Contact
Virginia Diaz
210-562-9149
diazvr@uthscsa.edu
Regulatory Point of Contact
Jaclyn Hung
210-450-5358
hungj@uthscsa.edu
Principal Investigator
Anne-Marie Langevin